Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
NCT ID: NCT05954169
Last Updated: 2024-07-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
16 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-08-07
Study Completion Date
2024-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of SHR4640 tablets in subjects with moderate renal insufficiency and healthy subjects, and to explore the relationship between renal function (e.g., eGFR) and SHR4640 pharmacokinetic and pharmacodynamic parameters.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects
NCT05948059
Kidney Transplantation
ENROLLING_BY_INVITATION
PHASE1
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
NCT06039254
Chronic Kidney Disease
UNKNOWN
PHASE1
A Study of SHR4010 in Patients With Hemodialysis
NCT04099927
Pruritus
COMPLETED
PHASE1
Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease
NCT06248567
Kidney Impairment
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment
NCT05947097
Renal Impairment
UNKNOWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hyperuricemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Single-dose, open
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group A in moderately renal insufficiency subjects
Group Type
EXPERIMENTAL
SHR4640
Intervention Type
DRUG
SHR4640 single-dose
Treatment group B in healthy subjects
Group Type
EXPERIMENTAL
SHR4640
Intervention Type
DRUG
SHR4640 single-dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SHR4640
SHR4640 single-dose
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Moderate renal impaired subjects:
1. Able and willing to provide a written informed consent.
2. 18 years to 65 years (inclusive).
3. Body mass index should be between 18 and 35 kg/m2 (inclusive).
4. eGFR should be between 30 and 59 mL/min/1.73 m2 (inclusive).
5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
6. If subjects with underlying diseases required drug treatment, the dose needs to be kept stable during study.
Healthy subjects:
1. Able and willing to provide a written informed consent.
2. 18 years to 65 years (inclusive).
3. Body mass index should be between 18 and 35 kg/m2 (inclusive).
4. eGFR should be ≥ 90 and \< 130 mL/min/1.73 m2.
5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
Moderate renal impaired subjects:
1. Able and willing to provide a written informed consent.
2. 18 years to 65 years (inclusive).
3. Body mass index should be between 18 and 35 kg/m2 (inclusive).
4. eGFR should be between 30 and 59 mL/min/1.73 m2 (inclusive).
5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
6. If subjects with underlying diseases required drug treatment, the dose needs to be kept stable during study.
Healthy subjects:
1. Able and willing to provide a written informed consent.
2. 18 years to 65 years (inclusive).
3. Body mass index should be between 18 and 35 kg/m2 (inclusive).
4. eGFR should be ≥ 90 and \< 130 mL/min/1.73 m2.
5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
Exclusion Criteria
\-
Moderate renal impaired subjects:
1. Pregnant or nursing women.
2. No birth control 2 weeks before screening or until one week after SHR4640 administration.
3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
5. Subject with a history of substance abuse and drug abuse.
6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
7. The investigators or relevant staff of the research centers or others directly involved in the study.
8. 2 weeks before SHR4640 administration sUA level ≥480 μmol/L.
9. Alanine aminotransferase and/or aspartate aminotransferase\>2×ULN, alkaline phosphatase (ALP)\>2.5×ULN.
10. Positive result for hepatitis B surface antigen.
11. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
12. White blood cell \< 3.0×109/L, and/or hemoglobin \<80 g/L, and/or platelet \<80×109/L.
13. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
14. History of hypersensitivity to SHR4640 or its analogues.
15. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
16. History of been diagnosed with acute kidney injury in the past or screening period.
17. History of kidney transplantation.
18. Renal dialysis required during the study.
19. Urinary incontinence or anuria (eg\< 100 mL/d).
20. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
21. Have grade III or IV congestive heart failure (New York Heart Association classification) or myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 1 year of screening, and other cardiovascular and cerebrovascular events leading to hospitalization.
22. History of active peptic ulcer within 1 year before screening, previous history of active gastrointestinal bleeding, gastrointestinal perforation, history of inflammatory bowel disease, or active peptic ulcer at screening.
23. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
24. SBP≥180 mmHg and/or DBP ≥110 mmHg.
25. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
26. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
27. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
28. Has unsuitable venous for blood sampling.
29. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
1\) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
2\) Unstable dosage of urate-lowering drugs within 6 weeks of Day 1. 3) Diuretics within 2 weeks of Day 1. 4) Aspirin in excess of 100 mg daily or unstable dose within the 2 weeks of Day 1.
5\) Unstable dosage of antihypertensive, lipid-lowering and hypoglycemic drugs within 2 weeks of Day 1.
6\) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
30\. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
31\. Taken prescription drugs, over-the-counter drugs, herbal medicines or food supplements other than drugs for the treatment of renal insufficiency and other concomitant diseases within 2 weeks before Day 1.
Healthy subjects:
1. Pregnant or nursing women.
2. No birth control 2 weeks before screening or until one week after SHR4640 administration.
3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
5. Subject with a history of substance abuse and drug abuse.
6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
7. The investigators or relevant staff of the research centers or others directly involved in the study.
8. 2 weeks before SHR4640 administration sUA level ≥420 μmol/L.
9. Laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) during the screening period were abnormal and the investigators determined that they were clinically significant.
10. Positive result for hepatitis B surface antigen.
11. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
12. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
13. History of hypersensitivity to SHR4640 or its analogues.
14. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
15. History of been diagnosed with chronic or acute kidney injury in the past or screening period. History of kidney transplantation.
16. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
17. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
18. SBP\>140 mmHg or \<90 mmHg and/or DBP \>90 mmHg or \<60 mmHg.
19. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
20. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
21. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
22. Has unsuitable venous for blood sampling.
23. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
1\) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
2\) Use of urate-lowering drugs within 6 weeks of Day 1. 3) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
24\. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
25\. Taken any prescription drugs, over-the-counter drugs, herbal medicines or food supplements within 2 weeks before Day 1.
Moderate renal impaired subjects:
1. Pregnant or nursing women.
2. No birth control 2 weeks before screening or until one week after SHR4640 administration.
3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
5. Subject with a history of substance abuse and drug abuse.
6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
7. The investigators or relevant staff of the research centers or others directly involved in the study.
8. 2 weeks before SHR4640 administration sUA level ≥480 μmol/L.
9. Alanine aminotransferase and/or aspartate aminotransferase\>2×ULN, alkaline phosphatase (ALP)\>2.5×ULN.
10. Positive result for hepatitis B surface antigen.
11. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
12. White blood cell \< 3.0×109/L, and/or hemoglobin \<80 g/L, and/or platelet \<80×109/L.
13. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
14. History of hypersensitivity to SHR4640 or its analogues.
15. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
16. History of been diagnosed with acute kidney injury in the past or screening period.
17. History of kidney transplantation.
18. Renal dialysis required during the study.
19. Urinary incontinence or anuria (eg\< 100 mL/d).
20. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
21. Have grade III or IV congestive heart failure (New York Heart Association classification) or myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 1 year of screening, and other cardiovascular and cerebrovascular events leading to hospitalization.
22. History of active peptic ulcer within 1 year before screening, previous history of active gastrointestinal bleeding, gastrointestinal perforation, history of inflammatory bowel disease, or active peptic ulcer at screening.
23. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
24. SBP≥180 mmHg and/or DBP ≥110 mmHg.
25. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
26. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
27. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
28. Has unsuitable venous for blood sampling.
29. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
1\) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
2\) Unstable dosage of urate-lowering drugs within 6 weeks of Day 1. 3) Diuretics within 2 weeks of Day 1. 4) Aspirin in excess of 100 mg daily or unstable dose within the 2 weeks of Day 1.
5\) Unstable dosage of antihypertensive, lipid-lowering and hypoglycemic drugs within 2 weeks of Day 1.
6\) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
30\. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
31\. Taken prescription drugs, over-the-counter drugs, herbal medicines or food supplements other than drugs for the treatment of renal insufficiency and other concomitant diseases within 2 weeks before Day 1.
Healthy subjects:
1. Pregnant or nursing women.
2. No birth control 2 weeks before screening or until one week after SHR4640 administration.
3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
5. Subject with a history of substance abuse and drug abuse.
6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
7. The investigators or relevant staff of the research centers or others directly involved in the study.
8. 2 weeks before SHR4640 administration sUA level ≥420 μmol/L.
9. Laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) during the screening period were abnormal and the investigators determined that they were clinically significant.
10. Positive result for hepatitis B surface antigen.
11. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
12. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
13. History of hypersensitivity to SHR4640 or its analogues.
14. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
15. History of been diagnosed with chronic or acute kidney injury in the past or screening period. History of kidney transplantation.
16. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
17. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
18. SBP\>140 mmHg or \<90 mmHg and/or DBP \>90 mmHg or \<60 mmHg.
19. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
20. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
21. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
22. Has unsuitable venous for blood sampling.
23. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
1\) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
2\) Use of urate-lowering drugs within 6 weeks of Day 1. 3) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
24\. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
25\. Taken any prescription drugs, over-the-counter drugs, herbal medicines or food supplements within 2 weeks before Day 1.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR4640-111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
NCT02815774
COMPLETED
PHASE1
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
NCT05505955
COMPLETED
PHASE1
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions
NCT04906798
UNKNOWN
PHASE1
Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects
NCT05638126
UNKNOWN
PHASE1
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
NCT02011490
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment
NCT05497297
COMPLETED
PHASE1
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
NCT02508506
COMPLETED
PHASE1
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
NCT00704678
COMPLETED
PHASE2
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment
NCT04859439
COMPLETED
PHASE1
A Study of SHR0410 in Hemodialysis Patients With Pruritus
NCT04317209
UNKNOWN
PHASE1
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
NCT07289763
NOT_YET_RECRUITING
PHASE2
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
NCT05847920
TERMINATED
PHASE2
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
NCT03864458
COMPLETED
PHASE2
Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers
NCT05089279
COMPLETED
PHASE1
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
NCT05698043
COMPLETED
PHASE1
Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy
NCT05136456
UNKNOWN
PHASE2
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions
NCT04906785
UNKNOWN
PHASE1
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients
NCT07201467
RECRUITING
PHASE1/PHASE2
Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease
NCT06221059
COMPLETED
PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
NCT04470154
COMPLETED
PHASE2
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
NCT05624723
COMPLETED
PHASE1
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
NCT05245084
COMPLETED
PHASE1
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions
NCT04142970
COMPLETED
PHASE1
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
NCT05468749
COMPLETED
PHASE1
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
NCT03161015
COMPLETED
PHASE1